Subsequently, we evaluated expression levels of these candidate genes based on clinical features and TP53 mutation status, and also investigated the correlations between their expression and immune cell infiltration in BC, as well as biomarkers of immune cells and immune checkpoints. The gene discussed is TP53; the disease is breast cancer.